These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 18427455

  • 1. [The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)].
    Boĭko AN, Batysheva TT, Minaeva NG, Babina LA, Vdovichenko TV, Zhuravleva EIu, Shikhkerimov RK, Malykhina EA, Khozova AA, Zaĭtsev KA, Kostenko EV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):21-4. PubMed ID: 18427455
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV, Odinak MM, Mogil'naia VI, Sologub OS, Sakharovskaia AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
    Silver DE.
    Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
    [Abstract] [Full Text] [Related]

  • 7. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).
    Myllylä V, Haapaniemi T, Kaakkola S, Kinnunen E, Hartikainen P, Nuutinen J, Rissanen A, Kuopio AM, Jolma T, Satomaa O, Heikkinen H.
    Acta Neurol Scand; 2006 Sep; 114(3):181-6. PubMed ID: 16911346
    [Abstract] [Full Text] [Related]

  • 8. [A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation].
    Fedotova EIu, Karabanov AV, Poleshchuk VV, Polevaia EV, Mirkasimov AF, Zagorovskaia TB, Ivanova-Smolenskaia IA, Illarioshkin SN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012 Sep; 112(5):50-5. PubMed ID: 22951782
    [Abstract] [Full Text] [Related]

  • 9. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS, Herawati L, Wan Y, Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group.
    Mov Disord; 2009 Jan 15; 24(1):25-31. PubMed ID: 18846551
    [Abstract] [Full Text] [Related]

  • 10. Levodopa/carbidopa/entacapone (Stalevo).
    Hauser RA.
    Neurology; 2004 Jan 13; 62(1 Suppl 1):S64-71. PubMed ID: 14718682
    [Abstract] [Full Text] [Related]

  • 11. [Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease].
    Fedorova NV, Levin OS, Smolentseva IG, Kulua TK.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006 Jan 13; 106(9):39-46. PubMed ID: 17069061
    [Abstract] [Full Text] [Related]

  • 12. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.
    Ann Neurol; 2010 Jul 13; 68(1):18-27. PubMed ID: 20582993
    [Abstract] [Full Text] [Related]

  • 13. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H, Emre M.
    Expert Rev Neurother; 2012 Feb 13; 12(2):119-31. PubMed ID: 22288667
    [Abstract] [Full Text] [Related]

  • 14. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr 13; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

  • 15. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
    Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, Pavon N, Macias R, Luquin MR, Hernandez B, Grandas F, Gimenez-Roldan S, Tolosa E, Obeso JA.
    Neurologia; 2005 May 13; 20(4):180-8. PubMed ID: 15891947
    [Abstract] [Full Text] [Related]

  • 16. Levodopa/carbidopa/entacapone in Parkinson's disease.
    Seeberger LC, Hauser RA.
    Expert Rev Neurother; 2009 Jul 13; 9(7):929-40. PubMed ID: 19589043
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ, Lees A, Apajasalo M, Pitkänen A, Turunen H.
    Curr Med Res Opin; 2005 Jul 13; 21(7):1005-14. PubMed ID: 16004667
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
    Müller T.
    Clin Neuropharmacol; 2013 Jul 13; 36(3):84-91. PubMed ID: 23673910
    [Abstract] [Full Text] [Related]

  • 20. [The effect of Stalevo-dosing on quality of life of Parkinsonian patients with wearing-off].
    Bokor M, Szentesi A.
    Ideggyogy Sz; 2010 Jul 30; 63(7-8):247-51. PubMed ID: 20812452
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.